This webinar series includes the presentations and the audience QAs recorded from the live broadcast and the associated slide handouts. If you would like continuing education credit for the webinars, click on the links in the table below to access the webinars + CME/CMLE or webinars + SAM
Series Description: Examining the mutational profile of tumors has become much easier because of the advances and accessibility of next-generation sequencing techniques. Analyzing the genetic signatures of tumors might identify patients who have higher chances of responding to checkpoint inhibition. Various studies have shown how the mutational burden correlates with greater efficacy of anti-PD-L1/PD-1 therapies, however tumor mutational burden (TMB) testing methodology and classification have not yet been standardized in clinical practice. This educational webinar series will provide information regarding current best practices in TMB testing, interpretation, and reporting.
Webinars include: (Click "Topic" tab for descriptions)
Duration: 3 hr
Level of Instruction: Basic
This is a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
Click on the links below to access continuing education credit.
You may also be interested in:
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
September 26, 2018
TMB Series 1
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00
Purchase Individual Topics